Title
Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors
A Pilot, Phase II , Open Label, Nonrandomized, Multi- Center Study of [F 18]HX4 Positron Emission Tomography (PET) to Detect Hypoxia in Tumors
Phase
Phase 2Lead Sponsor
SiemensStudy Type
InterventionalStatus
Completed Results PostedIndication/Condition
Head and Neck Cancer Lung Cancer Liver Cancer Rectal Cancer Cervical CancerIntervention/Treatment
hx4 ...Study Participants
50This pilot phase II study is designed as a test and retest study to investigate [F 18]HX4 as a reliable non-invasive PET imaging marker for detection of tumor hypoxia regions and to establish a threshold for [F 18]HX4 uptake in the tumor. The study will evaluate the relationship between hypoxia biomarkers (HIF1α and CA-IX) by immunohistochemistry (IHC) and tumor uptake of [F 18]HX4 by PET imaging.
A Pilot Phase II Study
The primary objectives for this study are:
To test the reproducibility of [F-18] HX-4 uptake in tumors by imaging the same patient on sequential days in a test-retest protocol
To test and confirm the relationship between hypoxia in tumors measured by hypoxia related biomarkers (HIF1α and CA-IX) with immunohistochemistry (IHC) and regional [F-18 HX-4] uptake in tumors with PET/CT.
The secondary objectives for this study are:
To continue safety evaluation by the collection of safety data from all patients
To establish the threshold for hypoxia uptake in [F- 18]HX4 PET imaging
To collect data to test [F-18]HX4 PET imaging as a predictor of response in a subgroup of patients receiving treatment
To gain experience with [F-18]HX4 PET/CT in order to improve the study design to conduct future studies
Design: An open label, non-randomized, uncontrolled, single group assignment, pilot efficacy study
Procedures: Informed consent, collection of demographic information, medical history, blood labs, physical examination, vital signs, ECGs, two or three sets of [F-18]HX4 dosing and imaging scans including two pretreatment, and one mid-treatment if [F-18]HX4 tumor/background ratio ≥ 1.3 from pre-treatment scans, one pre-treatment [F-18]FDG, one mid-treatment if [F- 18]HX4 tumor/background ratio ≥1.3 from pre-treatment scans, concomitant medication collection, adverse event monitoring, and assessment of tumor response to treatment
Patients: Approximately forty (40) patients who have diagnosis confirmed by histopathological examination of tumor tissue from head/neck, lung, liver, rectal or cervical cancers and will receive chemotherapy, radiation therapy or chemoradiotherapy. This allows for approximately 30 evaluable patients to complete this study at approximately six sites.
Approximately forty (40) patients who have diagnosis confirmed by histopathological examination of tumor tissue from head/neck, lung, liver, rectal or cervical cancers and will receive chemotherapy, radiation therapy or chemoradiotherapy, will be imaged under PET/CT with [F 18]HX4
[F18]HX4, 10 mCi, is administered in a single intravenous bolus injection, followed by a saline flush.
Inclusion Criteria: Patient is >18 years and male or female of any race / ethnicity Patient or patient's legally acceptable representative provides written informed consent and is willing to comply with protocol procedures Patient must have histopathologically confirmed head/neck, lung, liver, rectal or cervical cancer with tumor size ≥ 3cm Patient has tumor tissue samples available before treatment for future immunohistochemistry biomarker tests (HIF1alpha and CA-IX) Patient is scheduled to have or already had a clinical [F 18]FDG PET/CT scan recommended to be within 14 days of the first pre-treatment [F 18]HX4 PET/CT scan and have no treatment intervention in between these two scans Patient is scheduled or is intended to be scheduled to receive chemotherapy, radiation or chemoradiotherapy treatment(s) after the pre-treatment [F 18]HX4 PET/CT and [F 18]FDG PET/CT scans for his/her cancer care Patient must have hepatic and renal functions as defined by laboratory results within the following ranges: Total bilirubin within 2 times institutional upper limit of normal AST (SGOT) and ALT (SGPT) ≤ 2.5 times institutional upper limits of normal Serum creatinine ≤ 2.5 times institutional limit of normal BUN within 2 times institutional upper limit of normal Exclusion Criteria: Patient is not capable of complying with study procedures Female patient is pregnant or nursing o Exclude the possibility of pregnancy by one of the following: Confirming in medical history that the patient is post-menopausal for a minimum of one year, or surgically sterile Confirming the patient is using one of the following methods of birth control for a minimum of one month prior to entry into this study: IUD, oral contraceptives, Depo-Provera, or Norplant Confirming a negative urine dipstick test taken the morning of but before receiving [F 18]HX4 Patient has been involved in an investigative, radioactive research procedure within 7 days and during the study participation period Patient has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete data
| Event Type | Organ System | Event Term |
|---|
Primary tumor uptake of [F 18]HX4 was measured on PET images by onsite radiologist or nuclear medicine physician for 1st and 2nd PET scans. Values measured were: SUV (Standard Uptake Value), SUV Max (Maximum standard uptake value), SUV Mean (Mean standard uptake value), and T/B ratio (Tumor to background ratio). Pearson's correlation coefficient was calculated for each of the parameter.
